NF2 and cancer: The mechanism by which NF2 mutations drive cancer is unknown but recent results show that mutation in the FERM domain of NF2 lead to a gain-of-function ability to form biomolecular condensates that sequester and inactivate IRF3 and TBK1, disrupting the cGAS-Sting pathway (Figure 1B) [41].